We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellectricon Launches Cellaxess® Elektra Discovery Platform

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cellectricon has announced the new Cellaxess Elektra Discovery Platform which represents a revolutionary development in automated electric field manipulation of adherent cells.

Developed in close collaboration with leading pharmaceutical and biotechnology companies, the platform is highly diverse and can be applied to a wide variety of cellular manipulations in cell biology research.

The platform enables in-situ manipulation and monitoring of cell cultures directly in HCA compatible 96- and 384-well microplates at any cellular developmental stage with excellent viability and completely retained cellular morphology.

"We are very satisfied about the collaboration with Cellectricon. The Cellaxess Elektra opens a new dimension in RNAi delivery and high-throughput screening - that is the electroporation of primary adherent cell types." Dr. Robin Ketteler, Manager of the high-throughput screening facility at the MRC LMCB, University College London.
Applications for the Cellaxess Elektra include stimulation and voltage control of cultures in small molecule screening, transfection of siRNA and cDNA to primary cell cultures in genomic screening applications, as well as delivery of small molecules and antibodies in lead identification and target validation.

The Cellaxess® Elektra Discovery Platform can be equipped with an imaging-based microplate reader for recording of transient fluorescence and luminescence signals from living cells.